PIPEs have fallen out of favor. The private investment in public equity, or PIPE, had one of the best years on record in 2024. The financing instrument has a clubby feel in which drug developers typically share confidential trial data or other information with select investors to entice them to buy unregistered shares. Along with most go-to biopharma financing routes, the PIPE has frozen. There were nine PIPEs in the first quarter of 2025, compared to 34 in the same quarter of last year, according to data shared with Endpoints News by Raymond James.
Read the full article: PIPEs, Biopharma’s Favorite Financing Vehicle, Freeze amid Market Struggles //
Source: https://endpts.com/pipes-biopharmas-favorite-financing-vehicle-freeze-amid-market-struggles